- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT06503510
El papel de las vías de la interleucina-13 sobre el dolor y la sensibilidad al picor en pacientes con dermatitis atópica y voluntarios sanos (IL-13)
Atopic dermatitis (AD) is as chronic, inflammatory skin disorder affecting 20% of the world's population. Intense itch and skin pain are the main symptoms. Research has shown that the proteins interleukins are involved in inflammation and itch in atopic dermatitis. The medicinal product called Lebrikizumab, used for treatment of AD, has shown to block the interleukin called IL-13. The purpose of this experiment is to evaluate the role of IL-13 in itch in both healthy subjects and people with atopic dermatitis.
Descripción general del estudio
Estado
Condiciones
Intervención / Tratamiento
Descripción detallada
Atopic dermatitis (AD) is as chronic, inflammatory skin disorder affecting 20% of the world's population. Intense itch and skin pain are the main symptoms. Research has shown that the interleukin-13 is involved in inflammation and itch in atopic dermatitis by increasing the neuronal sensitivity to pruritogens. However, the physiological mechanisms by which IL-13 increases the itch sensitivity are unclear. The aim of this project is to use, for the first time in humans, the monoclonal antibody Lebrikizumab that inhibits IL-13 with high affinity as a novel experimental tool to modulate the IL-13 pathway and evaluate its role in the transmission and processing of itch and pain.
Tipo de estudio
Inscripción (Estimado)
Fase
- No aplica
Contactos y Ubicaciones
Estudio Contacto
- Nombre: Silvia Lo Vecchio
- Número de teléfono: 21397785
- Correo electrónico: slv@hst.aau.dk
Ubicaciones de estudio
-
-
Aalborg
-
Gistrup, Aalborg, Dinamarca, 9260
- Reclutamiento
- Aalborg University
-
Contacto:
- Silvia Lo Vecchio, PhD
- Número de teléfono: 21397785
- Correo electrónico: slv@hst.aau.dk
-
Contacto:
- Botilla Markussen
- Número de teléfono: 20567502
- Correo electrónico: bam@hst.aau.dk
-
Investigador principal:
- Silvia Lo Vecchio, PhD
-
Sub-Investigador:
- Botilla Markussen
-
Gistrup, Aalborg, Dinamarca, 9260
- Activo, no reclutando
- CNAP
-
-
Denmark
-
Aalborg, Denmark, Dinamarca, 9260
- Aún no reclutando
- Aalborg University
-
Contacto:
- Silvia Lo Vecchio
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria:
- Healthy men and women
- 18-60 years
Exclusion Criteria:
- Pregnancy or lactation
- Drug addiction defined as any use of cannabis, opioids, or other drugs
- Previous or current history of neurological, dermatological (e.g., AD, psoriasis, etc.), immunological, musculoskeletal, cardiac disorder, or psychiatric diagnoses that may affect the results (e.g., neuropathy, muscular pain in the upper extremities, anxiety, depression, schizophrenia, etc.)
- Moles, wounds, scars, or tattoos in the area to be treated or tested
- Current use of medications that may affect the trial such as antihistamines and pain killers (use of antihistamines should be discontinued 72 hours before the experiment and all topical agents and emollients should be discontinued 24 hours before the experiment).
- Use of systemic and topical corticosteroids
- Consumption of alcohol or painkillers 24 hours before the study days and between these
- Acute or chronic pain
- Participation in other trials within one week of study entry (four weeks in the case of pharmaceutical trials)
- Lack of ability to cooperate
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Asignación: N / A
- Modelo Intervencionista: Asignación de un solo grupo
- Enmascaramiento: Ninguno (etiqueta abierta)
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
|---|---|
|
Experimental: Lebrikizumab
The initial doses will be subcutaneous Lebrikizumab 500 mg (two 250 mg injections) at both week 0 (baseline) and week 2, followed by 250 mg administered subcutaneously at week 4. |
Approximately 30-35 cowhage spicules will be manually inserted into the subject's skin. A small drop of histamine dihydrochloride (1%, in saline) will be applied to a previously determined area on the volar forearm followed by a prick through the drop. A small drop of BAM8-22 solution will be applied to a previously determined area on the volar forearm followed by a prick through the drop. |
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Superficial blood perfusion
Periodo de tiempo: Baseline
|
Superficial blood perfusion (SBP) is measured by a Speckle contrast imager |
Baseline
|
|
Mechanically evoked itch (MEI)
Periodo de tiempo: Baseline
|
MEI is measured by using mildly pruritic, non-painful von Frey nylon filaments of a predetermined intensity (generally 5-30 miliNewton of force). |
Baseline
|
|
Measuring itch by computerized Visual Analog Scale Scoring
Periodo de tiempo: 1 minute after every itch induction
|
The subjects will be asked to rate the sensation of itch on a 100 mm VAS scale ranging from 0 to 100 where 0 indicates "no itch" and 100 indicates "worst itch imaginable". |
1 minute after every itch induction
|
|
Measuring pain by computerized Visual Analog Scale Scoring
Periodo de tiempo: 1 minute after every itch induction
|
The subjects will be asked to rate the sensation of pain on a 100 mm VAS scale ranging from 0 to 100 where 0 indicates "no pain" and 100 indicates "worst pain imaginable". |
1 minute after every itch induction
|
|
Superficial blood perfusion
Periodo de tiempo: 10 minute after every itch induction
|
Superficial blood perfusion (SBP) is measured by a Speckle contrast imager |
10 minute after every itch induction
|
|
Wheal reaction
Periodo de tiempo: 10 minute after every itch induction
|
Wheal reaction measurement will be conducted immediately after the removal of pruritogens by measuring the longest diameter with a ruler. |
10 minute after every itch induction
|
|
Average pruritis and pain numerical rating scale (NRS)
Periodo de tiempo: Baseline
|
The subject will be asked to retrospectively rate the average and worst itch/pain on an 11-point scale ranging from 0 to 10 (0 = no pain and 10 = worst imaginable pain)experience they had during the last 7 days. |
Baseline
|
|
Skin peak pain numerical rating scale (SPP-NRS)
Periodo de tiempo: Baseline
|
According to the SPP-NRS, the subject will be asked about "worst skin pain" they felt in the past 24 hours on an 11-point scale ranging from 0 to 10 (0 = no pain and 10 = worst imaginable pain) |
Baseline
|
|
Peak pruritus numerical rating scale (PP-NRS)
Periodo de tiempo: Baseline
|
The subject will be asked about the "worst itch" they felt in the past 24 hours on an 11-point scale ranging from 0 to 10 (0 = no itch and 10 = worst imaginable itch) |
Baseline
|
|
Mechanically evoked itch (MEI)
Periodo de tiempo: 10 minutes after every itch induction
|
MEI is measured by using mildly pruritic, non-painful von Frey nylon filaments of a predetermined intensity (generally 5-30 miliNewton of force). |
10 minutes after every itch induction
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Mechanical Pain Thresholds (MPT)
Periodo de tiempo: Baseline
|
This test is conducted using a pinprick set. The set consists of 7 needles each with a diameter of 0.6 mm and different force applications: 8, 16, 32, 64, 128, 256, and 512 mN. |
Baseline
|
|
Mechanical Pain Sensitivity (MPS)
Periodo de tiempo: Baseline
|
This test is conducted with the same pinprick set used to test the MPT. |
Baseline
|
|
Pressure Pain Thresholds (PPT)
Periodo de tiempo: Baseline
|
Pressure will be applied by a handheld electronic pressure algometer (Somedic AB, Stockholm, Sweden) on to the supinator muscle on the left forearm. |
Baseline
|
|
Cold Detection Thresholds (CDT)
Periodo de tiempo: Baseliene
|
The tests of thermal sensation will all be conducted using a TSA2 (Medoc Ltd, Israel) thermal sensory testing device |
Baseliene
|
|
Warm Detection Thresholds (WDT)
Periodo de tiempo: Baseline
|
The tests of thermal sensation will all be conducted using a TSA2 (Medoc Ltd, Israel) thermal sensory testingdevice |
Baseline
|
|
Cold Pain Thresholds (CPT)
Periodo de tiempo: Baseline
|
The tests of thermal sensation will all be conducted using a TSA2 (Medoc Ltd, Israel) thermal sensory testing device |
Baseline
|
|
Heat Pain Thresholds (HPT)
Periodo de tiempo: Baseline
|
The tests of thermal sensation will all be conducted using a TSA2 (Medoc Ltd, Israel) thermal sensory testing device |
Baseline
|
|
Pain to Supra-threshold Heat Stimuli (STHS)
Periodo de tiempo: Baseline
|
The tests of thermal sensation will all be conducted using a TSA2 (Medoc Ltd, Israel) thermal sensory testing device |
Baseline
|
Colaboradores e Investigadores
Patrocinador
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Finalización primaria (Actual)
Finalización del estudio (Estimado)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Términos MeSH relevantes adicionales
- Manifestaciones de la piel
- Enfermedades de la piel
- Condiciones Patológicas, Signos y Síntomas
- Enfermedades de la piel y del tejido conectivo
- Signos y síntomas
- Prurito
- Químicos orgánicos
- Compuestos heterocíclicos, 1 anillo
- Compuestos heterocíclicos
- Azoles
- Factores biológicos
- Imidazoles
- Amina
- Etilaminas
- Autacoides
- Mediadores de inflamación
- Monoaminas biogénicas
- Aminas biogénicas
- Histamina
- bovine adrenal medulla 8-22
Otros números de identificación del estudio
- N-20240029
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .